Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Maxvax Completes $74 Million Series B for China Vaccine Development

publication date: Jul 28, 2022

Chengdu’s Maxvax raised $74 million in a Series B round to support clinical trials of several pipeline vaccine candidates, including herpes zoster and rotavirus for neonates and children under 5 years. The company is currently developing more than ten new vaccines, with two candidates in clinical trials. It expects IND approvals for several more in the next year and will start R&D for animal vaccines as well. The B round was led by China Life Private Equity Investment, with Sherpa Investment, Hillhouse Venture Capital, Fangshizhen Capital and Xinshang Capital participating. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital